Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference
September 20 2023 - 3:05PM
Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today
announced that David-Alexandre C. Gros, M.D., Chief Executive
Officer, and Steve Perrin, Ph.D., President and Chief Scientific
Officer, will participate in a panel presentation at the upcoming
Cantor Fitzgerald Global Healthcare Conference on Wednesday,
September 27, 2023, at 8:00 a.m. ET.
To register in advance for the panel presentation webcast, sign
up here.
A webcast replay will be accessible following the live session
on the Events page of the Investors section on the Company’s
website
at https://ir.eledon.com/events-and-presentations/events.
About Eledon Pharmaceuticals and
tegoprubart
Eledon Pharmaceuticals is a clinical stage biotechnology
company with immunology expertise that is developing therapies to
protect and prevent rejection of transplanted organs, as well as to
treat amyotrophic lateral sclerosis (ALS). The Company’s lead
compound in development is tegoprubart, an anti-CD40L antibody with
high affinity for CD40 Ligand, a well-validated biological target
with broad therapeutic potential. Eledon is headquartered
in Irvine, California. For more information, please visit
the company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social
media: LinkedIn; Twitter
Investor Contact:
Stephen JasperGilmartin Group(858) 525
2047stephen@gilmartinir.com
Media Contact:
Jenna UrbanBerry & Company Public Relations(212) 253
8881jurban@berrypr.com
Source: Eledon Pharmaceuticals
Eledon Pharmaceuticals (NASDAQ:ELDN)
Historical Stock Chart
From May 2024 to Jun 2024
Eledon Pharmaceuticals (NASDAQ:ELDN)
Historical Stock Chart
From Jun 2023 to Jun 2024